Body composition in Prader-Willi syndrome compared with nonsyndromal obesity: Relationship to physical activity and growth hormone function

Edgar G. A. H. van Mil, MD, PhD, Klaas R. Westerterp, PhD, Willem-Jan M. Gerver, MD, PhD, Wouter D. Van Marken Lichtenbelt, PhD, Arnold D. M. Kester, PhD, and Wim H. M. Saris, MD, PhD

Objective: To study the relationship of fat mass, extracellular-to-intracellular-water ratio, and bone mineral density with growth hormone function and physical activity in Prader-Willi syndrome.

Study design: There were 17 patients with PWS (10 women, ages 7.5-19.8 years) and 17 obese control patients, matched for gender and bone age. FM and extracellular-to-intracellular-water ratio were measured by bromide-deuterium dilution, BMD by dual-energy x-ray absorptiometry, GH function by fasted serum insulin-like growth factor-I concentration, and physical activity by doubly-labeled water in combination with basal metabolic rate by a ventilated hood.

Results: The PWS group had a similar fat mass, but a lower fat-free mass, whereas the extracellular-to-intracellular-water ratio was higher compared with the control group (0.87 ± 0.07 l/l and 0.80 ± 0.06 l/l, respectively [P < .01]). Fat mass was inversely related with PA in the PWS group, whereas IGF-I was positively correlated with FFM, ICW, and BMD of the limbs. BMD tended to be lower in patients with PWS.

Conclusions: In children and adolescents with PWS, adiposity is associated with a reduced fat-free mass and extracellular-to-intracellular-water ratio is increased. Both findings are related to GH function and physical activity. BMD, especially in the limbs, tends to be reduced in patients with PWS and is related to GH function. (J Pediatr 2001;139:708–14)

Prader-Willi syndrome is known as a syndrome of hypotonia, hypogonadism, mental retardation, and obesity and is a complex genetic disorder that results from the absence of normally active paternally inherited genes at chromosome 15(q11-13). Despite early interventions, obesity is still one of the major causes of morbidity and mortality in patients with PWS. The main characteristics of PWS, supported by other clinical features such as short stature, delayed or incomplete puberty, and osteoporosis, suggest abnormalities of the somatotropic and hypothalamic-pituitary-gonadal axis. However, a structural lesion has not yet been discovered. Moreover, the pattern of adiposity in patients with PWS and the reduced lean mass, including reduced bone mass, especially in the limbs, have a close resemblance to the body composition present in children with growth hormone deficiency. Although GHD cannot be confirmed in all patients, the effect of growth hormone intervention does support a functional GHD. Consequently, a functional GHD might result in an increased extracellular-to-intracellular-water ratio as was shown in adults with GHD.

Another possible factor that may influence these alterations in body composition is inactivity. Children with PWS...
are less active than nonsyndromal children.\textsuperscript{11} Although the inverse relationship between obesity and activity has been established in nonsyndromal or primary obesity,\textsuperscript{12-14} it is unclear whether this relationship also exists in secondary obesity, such as PWS. The hypothesis was that activity and GH function would have an inverse relationship with adiposity in patients with PWS. Furthermore, it was hypothesized that the ECW/ICW ratio would be inversely related to GH function, indicating a functional GHD in children with PWS.

The aim of the present study, therefore, was to measure fat mass, body water compartments, and bone mineralization in patients with PWS compared with control patients with nonsyndromal obesity matched for gender and bone age, and to associate these body composition parameters with GH function and physical activity in patients with PWS.

**Methods**

**Patients**

Patients (n = 17, ages 7.5–19.8 years) were recruited with the assistance of the Dutch Prader-Willi Association. The patients were assessed according to the Holm criteria,\textsuperscript{3} which provides a quantitative measure of PWS symptoms. PWS was preferably confirmed by either a deletion on chromosome 15 or uniparental disomy. When only clinical data were available, critical evaluation took place by the same clinical geneticist. The patients with PWS were gender- and bone-age-matched with nonsyndromal obese control patients (ages 6.3–15.3 years) recruited from the regional public health department. Bone age measurement, a means of assessing the rate of maturational change throughout the growing period, provides an estimate of biological maturation, and therefore, is a better matching criterion than calendar age.\textsuperscript{15} Bone age was determined by assessing epiphyseal maturation by the same pediatric endocrinologist with the use of a radiograph of the midportion of the left hand and standard growth data.\textsuperscript{16} None of the patients with PWS were receiving hormone therapy or treatment with human GH before or during the study. Control patients with endocrine causes or other secondary causes of obesity were excluded from this study (Table I). All patients were measured in the summer months to avoid the potential confounding factor of seasonal variation in activity.\textsuperscript{17}

Before the start of the study, parents gave written informed consent that was further confirmed with an oral approval by the child. The study was approved by the medical ethics committee of Maastricht University, the Netherlands.

**General Outline of Protocol**

Total energy expenditure or average daily metabolic rate and total body water were measured according to the Maastricht Protocol for the measurement of body composition and energy expenditure with labeled water. The Maastricht protocol is based on measurements of stable isotopes in the urine, after the patient has received an orally administered stable isotope mixture. The protocol has been previously described in detail.\textsuperscript{18-20} Total body weight was measured on an electronic scale (E1200, Mettler Instumente AG, Greifensee, Switzerland) in the morning before the patients consumed any food or drink, after voiding, and while wearing underclothing. The heights of the patients without shoes was measured by using a stadiometer. Furthermore, a total body scan was made with a dual energy x-ray absorptiometer (DPX-L, Lunar Corp, Madison, Wis).

**Basal Metabolic Rate**

The basal metabolic rate measurement was started after the patients had lain supine for 10 minutes. Oxygen consumption and carbon dioxide production were measured for 40 to 50 minutes by use of a computerized, open circuit ventilated hood system as the patient watched television.\textsuperscript{19,20}

**ADMR and Activity by Doubly-labeled Water**

The isotope disappearance rates in the urine from the samples of days 1, 8, and 14 were used to calculate carbon dioxide production, which was converted to ADMR with a respiratory exchange ratio equal to the food quotient derived from a 1-week food diary calculated by a dietician. The total observed variance in ADMR, plotted as a function of BMR, can be subdivided into 2 components, one that is attributable to the regression with BMR and one that is not attributable to this regression, the residual of the regression. The residual of each patient represents the variance in PA-related energy expenditure and can be used as a relative measure of PA. Activity-related energy expenditure was, therefore, defined as the residual from the regression of ADMR with BMR (rADMR) (Fig 1). This measure was chosen instead of the PA index (ADMR/BMR), because of the nonzero intercept in the regression of AMDR with BMR. The use of ADMR/BMR may lead to a misinterpretation of the PA level in the younger patients with lower values of BMR.\textsuperscript{21,22}
Table I. Patient characteristics (shown as mean ± SD)

<table>
<thead>
<tr>
<th></th>
<th>PWS (n₁ = 17)</th>
<th>Control (n₂ = 17)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (F:M)</td>
<td>10:7</td>
<td>10:7</td>
</tr>
<tr>
<td>Bone age (y)</td>
<td>12.7 ± 2.9</td>
<td>12.7 ± 3.2</td>
</tr>
<tr>
<td>Age (y)</td>
<td>11.9 ± 3.4</td>
<td>11.5 ± 2.6</td>
</tr>
<tr>
<td>Tanner (1-5)</td>
<td>2.6 ± 1.6</td>
<td>2.6 ± 1.7</td>
</tr>
<tr>
<td>Height (m)</td>
<td>1.45 ± 0.16</td>
<td>1.49 ± 0.20</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>50.0 ± 19.7</td>
<td>61.5 ± 25.6</td>
</tr>
</tbody>
</table>
| BMI (kg/m²)      | 23.5 ± 6.0    | 26.0 ± 6.5       

Body Composition by Deuterium Dilution

Fat-free mass was assessed with the assumption of FFM containing TBW, which was calculated from isotope abundance in the urine, as the 2H dilution space divided by 1.04, correcting for exchange of the 2H label with nonaqueous H of body solids. Hydration factors of FFM were figured on the basis of gender- and maturation-specific values. Maturation was assessed according to Tanner’s puberty ratings. With the use of a 2-compartment model, FFM was calculated by subtracting FFM from the patient’s total body weight and also expressed as a percentage of the patient’s total body weight (%FM). To allow for comparisons between patients, FM and FFM were expressed as an index, FFM (kg/m²) and FMI (kg/m²), respectively. Patients with PWS have a typical pattern of growth, such as a stunting in growth during adolescence that leads to changes in age-related body composition. In this way, we have corrected for the large variation in height, analogous with BMI, where BMI = FFM + FMI.

Extracellular Water

TBW can be divided into ICW and ECW. The ECW compartment was determined by bromide dilution, and the bromide concentration was determined from serum after a 10-hour fast. Corrected bromide space was calculated according to the method of Miller et al. ICW is calculated by subtracting ECW from TBW.

Bone Mineral Content, Bone Mineral Density, and Percentage of FFM by DXA

Total bone mineral content and total bone mineral density were measured on the same day by DXA with the use of a pediatric scan mode. BMC was measured as total mass and calculated as a percentage of FFM as determined by DXA. BMD and BMC were calculated separately for the limbs (BMDlimb, BMClimb). All DXA measurements were calculated by Lunar software (version 1.5g, Lunar Corp, Madison, Wis). Furthermore, %FM was calculated as an alternative measurement to be compared with %FM provided by the deuterium dilution method.

Measurement of Serum Insulin-like Growth Factor-I

The serum insulin-like growth factor-I concentration was measured by using a commercially available assay (RIA, Nichols Institute Diagnostics, San Juan Capistrano, Calif). IGF-I was determined only in the group with PWS by a measurement performed in serum taken from a fasted venous blood sample.

Statistical Analysis

Differences between the independent variables of the group with PWS and the obese control group were analyzed by the 2-sample t test. A multiple-linear-regression model, with FMI as the dependent variable and FFM as the independent variable, was used to analyze the difference in FMI between the PWS and control groups, defined by the binary variable PWS status. In this analysis, FMI is a function of FFMI. The difference of the influence of FFMI on FMI in regression slope was tested by using an interactive variable of PWS status and FFMI, after correction for FFMI in the equation. Consequently, the difference between groups, corrected for FFMI, was estimated and tested for significance by using linear regression and assuming equal slopes. The same procedure was followed for ECW/ICW as the dependent variable, and bone age, FMI, gender, PWS status, and rADMR as independent variables were used to analyze the difference between both groups, adjusted for the independent variables.

Specifically for the group with PWS, the partial correlation coefficients of IGF-I and ECW/ICW, and of IGF-I and ICW, adjusted for bone age and FMI, were calculated. In addition, the correlation coefficients of IGF-I and FM, and of IGF-I and FFM, adjusted for bone age, were assessed. Third, the partial correlation coefficients of IGF-I and measures of bone mineralization, adjusted for bone age and body weight, were calculated. The significance level was chosen at 5%. Data were expressed as mean ± SD. SPSS release 6.1 for Macintosh (SPSS Inc, Chicago, Ill) was used as the statistical package.

Results

Age, height, weight, and BMI of the patients of the PWS and obese control groups were not significantly different (Table I). Sexual maturation in both groups ranged from pre- to postpubescent.

FFM and FFMI were lower in the group with PWS, whereas FM, %FM, and FMI values were not significantly different. However, when FMI was expressed as a function of FFMI, the regression slopes were similar and the group difference was significant, as was evident from multiple regression. TBW,
measured by deuterium dilution technique, was significantly lower in the group with PWS. ECW and ICW were lower; however, ECW/ICW was higher in the group with PWS. Because of difficulties we had in obtaining blood samples, ECW values were not obtained in 1 patient with PWS and 1 patient in the control group (Table II). %FM measured by DXA was comparable with %FM measured by deuterium dilution (PWS, 43.7 ± 7.9% and 44.9 ± 8.9%; control, 39.1 ± 8.8%, and 40.2 ± 12.1%, respectively; Pearson’s correlation, 0.95 (P < .0001).

BMC, expressed as a percentage of FFM, was higher in the group with PWS; however, the other measurements of bone mineralization, though not significant, tended to be lower in the group with PWS, especially for the limbs (Table II).

The increased ECW/ICW in the group with PWS was confirmed by multiple regression, correcting for bone age, FMI, gender, and PA. By using this model, other significant determinants in explaining the variance in ECW/ICW, besides PWS status, were bone age and FMI.

### Table II. Body composition results by deuteriumbromide dilution technique and DXA of patients with PWS and obese control patients

<table>
<thead>
<tr>
<th></th>
<th>PWS (n1 = 17)</th>
<th>Control (n2 = 17)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FFM (kg)</td>
<td>27.5 ± 9.9‡</td>
<td>35.9 ± 13.4</td>
</tr>
<tr>
<td>FFMI (kg/m²)</td>
<td>12.9 ± 2.3§</td>
<td>15.4 ± 2.7</td>
</tr>
<tr>
<td>FM (kg)</td>
<td>22.4 ± 11.7</td>
<td>25.6 ± 12.7</td>
</tr>
<tr>
<td>FMI (kg/m²)</td>
<td>10.6 ± 4.5</td>
<td>10.6 ± 4.0</td>
</tr>
<tr>
<td>TBW (L)</td>
<td>20.5 ± 7.1‡</td>
<td>26.7 ± 9.8</td>
</tr>
<tr>
<td>ECW (L)†</td>
<td>9.6 ± 3.3‡</td>
<td>12.3 ± 4.1</td>
</tr>
<tr>
<td>ECW/ICW†</td>
<td>0.87 ± 0.07§</td>
<td>0.80 ± 0.06</td>
</tr>
<tr>
<td>TBMC (g)</td>
<td>1564 ± 590</td>
<td>1897 ± 803</td>
</tr>
<tr>
<td>TBMClimbs (g)</td>
<td>315 ± 145</td>
<td>439 ± 216</td>
</tr>
<tr>
<td>TBMD (g/cm²)</td>
<td>1.005 ± 0.126</td>
<td>1.036 ± 0.152</td>
</tr>
<tr>
<td>TBMDlimbs (g/cm²)</td>
<td>0.832 ± 0.157</td>
<td>0.888 ± 0.181</td>
</tr>
</tbody>
</table>

*Mean ± SD.
†n1 = n2 = 16
‡Significantly different from control group (Independent-samples t test):
§P < .05.
¶P < .01.

Fig 2. Comparison of FMI with activity. FMI, in kg/m², as a function of activity-related energy expenditure (rADMR, in MJ/d) plotted for the group with PWS (filled circles) and the control group (open squares). The regression line of the control patients was not significant. The dotted line represents the mean FMI of the control group. The regression equation for PWS: 
FMI = –3.30 rADMR + 8.75 (r² = 0.36; P < .05).

MJ/d, Megajoules per day.

**DISCUSSION**

Previous reports have shown a combination of increased FM and reduced FFM in patients with PWS. The present results demonstrate that adiposity in patients with PWS is characterized by an underdevelopment of FFM and not excessive growth of FM. The absolute and relative measures of fat mass (FM, FMI, and %FM) were similar, whereas FFM in absolute value and corrected for height (FFMI) was significantly lower in the group with PWS. Moreover, multiple regression demonstrated that if FMI was plotted as a function of FFMI, the linear regression line through the PWS group was drawn parallel with, though underneath, the line of the control group. The use of indices for FFMI and FM, which correct for height, offer a comparison in body composition on the basis mainly of body weight, analogous with BMI, and they are especially valuable in children with a typical pattern of growth, like patients with PWS.

With these indices, it now becomes clear that the low FFM in patients with PWS is the reason that adiposity levels between groups can be similar, despite the tendency of an average higher BMI in the control group. BMI underestimates the adiposity in patients with PWS and is not the appropriate measure for those patients’ comparison with non-syndromal patients. The underdevelopment of FFM as the basis for adiposity in PWS might be caused by a functional GHD, as supported by the positive rela-
Although the effect of PA on FFM is well established, the relationship between activity and FM in healthy children and adults is still in debate. Some studies have shown a positive relationship between activity-related energy expenditure and adiposity, mainly because of the increasing energy costs for weight-bearing activities. Other studies reported no effect of adiposity on PA when corrected for body weight or BMR. In the present study, the control group showed no effect of activity-related energy expenditure on adiposity (corrected for BMR), whereas in patients with PWS, adiposity was inversely related with PA. Because the data in the present study were obtained in a cross-sectional manner, it remains unclear whether reduced PA in patients with PWS causes an increase in FM or the higher level of FM restricts them from being physically active.

It has been speculated that, besides GHD and physical inactivity, puberty delay could also be responsible for the reduction in FFM. In the present study, the patients were matched for bone age and gender, resulting in a similar puberty development, ranging from pre- to postpubescent, as was confirmed by the sexual maturation stages of Tanner. In spite of the similarity in puberty development and sexual maturation, the reduction of FFM was still present and does not support puberty delay as an explanatory factor for this reduction.

### Table III. Partial correlation coefficients of IGF-I and body composition parameters in patients with PWS

<table>
<thead>
<tr>
<th>Variable</th>
<th>Partial correlation</th>
<th>Partial correlation coefficient</th>
</tr>
</thead>
<tbody>
<tr>
<td>FM</td>
<td>IGF-I, adjusted for bone age</td>
<td>–0.51</td>
</tr>
<tr>
<td>FFM</td>
<td>IGF-I, adjusted for bone age</td>
<td>0.60†</td>
</tr>
<tr>
<td>ECW/ICW</td>
<td>IGF-I, adjusted for bone age and FMI</td>
<td>0.06</td>
</tr>
<tr>
<td>ICW</td>
<td>IGF-I, adjusted for bone age and FMI</td>
<td>0.77†</td>
</tr>
<tr>
<td>TBMD</td>
<td>IGF-I, adjusted for bone age and body weight</td>
<td>0.37</td>
</tr>
<tr>
<td>BMDlimbs</td>
<td>IGF-I, adjusted for bone age and body weight</td>
<td>0.63*</td>
</tr>
</tbody>
</table>

*P < .05.
†P < .01.

The reduced lean body mass in patients with PWS resembles that of persons with GHD. In adults, GHD is associated with shrinking of the ICW compartment, possibly as a result of protein catabolism. The higher ECW/ICW ratio in the group with PWS seems to support the hypothesis of functional GHD. Adiposity, however, also increases the ECW compartment (plasma water, interstitial water [including lymph], and connective tissue water [including bone and cartilage]), as was demonstrated in healthy obese children. The strong relation of ECW to FM is thought to be one of the reasons why a high ratio of ECW/ICW is associated with cardiovascular diseases such as hypertension. Furthermore, it is known that ECW/ICW shows a gender-specific decrease during maturation; therefore, multiple linear regression is needed to correct for the effect of adiposity and gender on ECW/ICW. The present results show that, even when corrected for adiposity, gender, and physiological maturation, ECW/ICW was higher in the group with PWS compared with the nonsyndromal obese control group. Possibly, this is explained by a combination of 2 separate effects, (1) increasing ECW caused by adiposity; and (2) decreased ICW as a result of diminished GH function, as is indicated by the positive correlation between IGF-I and ICW (Table III).

Although the fasting level of IGF-I cannot be used as the “gold standard” for GH function, IGF-I is known to be principally regulated by GH and proposed to be used as a marker for GH status in disturbed GH secretion. In healthy children, IGF-I changes with age, puberty development, and outdoor temperature, when short-term variations are mainly influenced by weight changes and illness. All of these factors were controlled for in the present study. Although IGF-I levels in patients with PWS have been reported to range from normal to subnormal, as was confirmed in the present study, it may still be possible, arguably, that the GH function is diminished because of a loss of sensitivity for GH metabolites.

It has been reported that adolescent patients with PWS may fracture their bones easily after minor trauma. A functional GHD in patients with PWS could be responsible for the specific reduction of bone mass in the limbs. The positive association between IGF-I and ECW/ICW, each via a different mode of action, suggests that, besides GHD, physical inactivity, and obesity, puberty delay may also contribute to bone loss in patients with PWS. It is known that adolescent patients with PWS may fracture their bones easily after minor trauma. A functional GHD in patients with PWS could be responsible for the specific reduction of bone mass in the limbs. The positive association between IGF-I and ECW/ICW, each via a different mode of action, suggests that, besides GHD, physical inactivity, and obesity, puberty delay may also contribute to bone loss in patients with PWS.
action. IGF-I would lead to an increase in FFM, whereas PA decreases FM, in both cases decreasing the level of adiposity. Consequently, the decrease in FM would lead to a decrease in ECW/ICW. This reduction in ECW/ICW would also be achieved when ICW is increased as a result of increased levels of IGF-I. Furthermore, IGF-I may have an additional positive effect on BMD/limbs. If a positive effect of PA on body composition exists in patients with PWS, it might lead to alternative intervention strategies that combine PA with hormonal therapy to prevent the development of obesity in patients with PWS.

We thank Drs L. M. G. Curfs and C. T. R. M. Schrander-Stumpel from the department of Clinical Genetics, the Dutch Prader-Willi Association, the public health department of the Maastricht region, and, particularly, the children and their parents for participating and making the study possible.

REFERENCES


10. Marken-Lichtenbelt WDv, Snell YEM, Brummer RJM, Koppeschaar HPF. Deuterium and bromide dilution, and bioimpedance spectrometry independently show that growth hormone-deficient adults have an enlarged extracellular water compartment related to intracellular water. J Clin Endocrinol Metab 1997;82:907-11.


